Pancreatic Cancer Research

ResearcherNational Institutes of HealthActive in the last 2 years

Vladimir Y. Bogdanov

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4968-1129; OpenAlex author ID A5046314701; NIH RePORTER profile ID 7603247. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 5)
Trials
0
Grants
3
Labs led
1
Collaborators
20
Papers, trials and grants by year

2012: 1 paper · 2013: 1 grant · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 1 grant · 2018: none · 2019: 1 grant · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 8

  1. Targeting Hsp70 Immunosuppressive Signaling Axis with Lipid Nanovesicles: A Novel Approach to Treat Pancreatic Cancer. Co-author DOI 10.3390/cancers17071224↗
  2. First-in-Class Humanized Antibody against Alternatively Spliced Tissue Factor Augments Anti-Metastatic Efficacy of Chemotherapy in a Preclinical Model of Pancr… Last author DOI 10.3390/ijms25052580↗
  3. A First-In-Class, Humanized Antibody Targeting Alternatively Spliced Tissue Factor: Preclinical Evaluation in an Orthotopic Model of Pancreatic Ductal Adenocar… Last author DOI 10.3389/fonc.2021.691685↗
  4. Enhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-Targeted Nanovesicles against Pancreatic Cancer. Co-author DOI 10.1016/j.ymthe.2020.05.013↗
  5. Antibody-based targeting of alternatively spliced tissue factor: a new approach to impede the primary growth and spread of pancreatic ductal adenocarcinoma. Last author DOI 10.18632/oncotarget.7955↗
  6. Levels of Alternatively Spliced Tissue Factor in the Plasma of Patients with Pancreatic Cancer May Help Predict Aggressive Tumor Phenotype. Last author DOI 10.1245/s10434-015-4592-2↗
  7. Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ijc.28327↗
  8. Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Co-author DOI 10.1182/blood-2012-01-402156↗

Grants 3

  1. Alternatively Spliced Tissue Factor and Pathobiology of Pancreatic Cancer R01CA190717↗
  2. Disrupting Tissue Factor-beta1 Integrin Axis in Pancreatic Cancer AWARD pancan:2017-vladimir-bogdanov-disrupting-tissue-factor-beta1-integrin-
  3. Tissue Factor splicing and pancreatic tumor progression: pilot studies R21CA160293↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Clayton S. Lewis · 5 shared papers, 2016–2025 · strength 0.71
  2. Xiaoyang Qi · 4 shared papers, 2014–2025 · strength 0.41
  3. Jen Jen Yeh · 3 shared papers, 2012–2024 · strength 0.34
  4. Harold W. Davis · 2 shared papers, 2020–2025 · strength 0.33
  5. Syed Ameen Ahmad · 4 shared papers, 2014–2021 · strength 0.31
  6. Ahmet Kaynak · 1 shared paper, 2025 · strength 0.22
  7. Petr Müller · 1 shared paper, 2025 · strength 0.22
  8. Davendra P. S. Sohal · 1 shared paper, 2024 · strength 0.21
  9. Zhengtao Chu · 3 shared papers, 2014–2020 · strength 0.19
  10. Dusten J. Unruh · 3 shared papers, 2014–2016 · strength 0.13
  11. Kombo F. N’Guessan · 1 shared paper, 2020 · strength 0.11
  12. Olugbenga Olanrele Olowokure · 1 shared paper, 2020 · strength 0.11
  13. Nigel Mackman · 2 shared papers, 2012–2016 · strength 0.07
  14. Alisa S. Wolberg · 2 shared papers, 2012–2016 · strength 0.07
  15. Syed Arif Ahmad · 1 shared paper, 2015 · strength 0.05
  16. Georg F. Weber · 1 shared paper, 2016 · strength 0.05
  17. Holger Kalthoff · 1 shared paper, 2014 · strength 0.03
  18. Julia E Geddings · 1 shared paper, 2012 · strength 0.03
  19. Nigel S. Key · 1 shared paper, 2012 · strength 0.03
  20. Jian-Guo Wang · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.